TATVA Tatva Chintan Pharma Chem Q1 FY26 results (Apr–Jun 2025) and concall
Tatva Chintan delivered a strong Q1 FY26, with operating revenue growing 11% YoY to INR 1,169 million and EBITDA surging 37% YoY to INR 173 million, driven by robust performance in PASC and SDA segments. The company is optimistic about future growth from new product commercializations and Euro 7 norms for SDA, despite persistent geopolitical uncertainties and the announced departure of its CFO.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|
| Revenue | 86 | 108 | 117 |
| EBITDA | 7 | 9 | 17 |
| Net profit | 0 | 1 | 7 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
